Press release
Post Bariatric Hypoglycemia Market is set for steady growth, with a robust CAGR anticipated by 2034, estimates DelveInsight
Post-Bariatric Hypoglycemia Market
Discover Key Insights into the Post Bariatric Hypoglycemia Market with DelveInsight's In-Depth Report @ Post Bariatric Hypoglycemia Market Size- https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Post Bariatric Hypoglycemia Market Report
• In 2023, the total postbariatric hypoglycemia cases in the 7MM were estimated to be approximately 110,000 cases which, as per DelveInsight's estimates, will increase by 2034.
• In 2023, the US accounted for the highest cases of postbariatric hypoglycemia with approximately 80% cases.
• As per DelveInsight's analysis, in 2023, there were higher cases of postbariatric hypoglycemia in sleeve gastrectomy cases, which was followed by Roux-en-Y gastric bypass cases, and cases in others in the US.
• As per severity of postbariatric hypoglycemia, there were more than 90% cases in the mild to moderate category in 2023, in the United States.
• There were nearly 50,000 treated cases of postbariatric hypoglycemia in 2023 in the United States.
• The leading Post-Bariatric Hypoglycemia companies such as XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan N.V., Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Micro Labs Ltd, and others.
• Promising Post-Bariatric Hypoglycemia Therapies such as Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, and others.
Stay ahead in the Post Bariatric Hypoglycemia Therapeutics Market with DelveInsight's Strategic Report @ Post Bariatric Hypoglycemia Market Outlook- https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Post Bariatric Hypoglycemia Epidemiology Segmentation in the 7MM
• Post Bariatric Hypoglycemia Type-specific Bariatric Surgery Cases
• Postbariatric Hypoglycemia Cases in types of Bariatric Surgeries
• Severity-specific Postbariatric Hypoglycemia Cases
• Total Post Bariatric Hypoglycemia Treated cases
Download the report to understand which factors are driving Post Bariatric Hypoglycemia epidemiology trends @ Post Bariatric Hypoglycemia Prevalence- https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Postbariatric Hypoglycemia Emerging Drugs Profile
• Mizagliflozin: Vogenx
Mizagliflozin follows an oral route of administration and minimally absorb the inhibitor of Sodium-glucose transporter 1 (SGLT1). Postbariatric Hypoglycemia patients have elevated SGLT1 levels in the gut. This elevated blood glucose stimulates uncontrolled insulin secretion in postbariatric hypoglycemia patients. In February 2024, Vogenx announced completion of patient enrollment of a mid-Phase II clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients diagnosed with post-bariatric hypoglycemia.
• AVEXITIDE (exendin 9-39): Eiger BioPharmaceuticals
AVEXITIDE (exendin 9-39) is a 31-amino acid peptide that selectively targets and blocks GLP-1 receptors, reducing dysregulated insulin secretion by the pancreas and reducing fasting and postprandial hypoglycemia. In June 2023, the company announced that the US FDA has granted breakthrough therapy designation to AVEXITIDE for the treatment of postbariatric hypoglycemia.
Postbariatric Hypoglycemia Market Outlook
Most of the therapies are based on case series or reports and extrapolated from their use in other conditions that cause hypoglycemia. Acarbose has been used as first-line treatment, although adverse gastrointestinal symptoms limit this option. Diazoxide and octreotide have been used with mixed results, but side effects and patient nonadherence limit their utility. Interestingly, exogenous GLP-1 receptor agonists have also demonstrated improvement in PBH, possibly through down regulation of insulin secretion from β-cells and increased secretion of glucagon from α-cells during conditions of hypoglycemia.
Get In-Depth Knowledge on Post Bariatric Hypoglycemia Market Trends and Forecasts with DelveInsight @ Post Bariatric Hypoglycemia Treatment Market- https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Post Bariatric Hypoglycemia Market Report
• Coverage- 7MM
• Post-Bariatric Hypoglycemia Companies- XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan N.V., Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Micro Labs Ltd, and others.
• Post-Bariatric Hypoglycemia Therapies- Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, and others.
• Post Bariatric Hypoglycemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Post Bariatric Hypoglycemia Unmet Needs, KOL's views, Analyst's views, Post Bariatric Hypoglycemia Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight's Comprehensive Post Bariatric Hypoglycemia Market Report @ Post Bariatric Hypoglycemia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Postbariatric Hypoglycemia (PBH) Market Overview at a Glance
4. Executive Summary of Postbariatric Hypoglycemia
5. Disease Background and Overview
6. Methodology
7. Epidemiology and Patient Population
8. Patient Journey
9. Emerging Therapies
10. Postbariatric Hypoglycemia (PBH): Seven Major Market Analysis
11. KOL Views
12. SWOT Analysis
13. Unmet Needs
14. Market Access and Reimbursement
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
List of Top Selling Market Research Reports in 2025
Surgical Lasers Market - https://www.delveinsight.com/report-store/surgical-lasers-market
Intraocular Lens Market - https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Myeloproliferative Neoplasms Market - https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Skin Neoplasm Market - https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Healthcare Competitive Benchmarking - https://www.delveinsight.com/consulting/competitive-benchmarking-services
Microscopy Device Market - https://www.delveinsight.com/report-store/microscopy-device-market
Pacemakers Market - https://www.delveinsight.com/report-store/pacemakers-market
Urea Cycle Disorders Market - https://www.delveinsight.com/blog/urea-cycle-disorder-market
Novel Drug Delivery Devices Market - https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Nk Cell Therapy Market - https://www.delveinsight.com/infographics/nk-cell-therapy-market
Surgical Mask & Respirator Market - https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Lymphoedema Market - https://www.delveinsight.com/report-store/lymphoedema-market
Phototherapies For Psoriasis Market - https://www.delveinsight.com/report-store/phototherapy-devices-market
Sepsis Market - https://www.delveinsight.com/report-store/sepsis-market
Bone Growth Stimulator Market - https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody Drug Conjugate Market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Overactive Bladder Syndrome Market - https://www.delveinsight.com/report-store/underactive-bladder-market
Medical Marijuana Market - https://www.delveinsight.com/report-store/medical-marijuana-market
Lactose Intolerance Market - https://www.delveinsight.com/report-store/lactose-intolerance-market
Catheter Stabilization Devices Market - https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market
Dyspepsia Market - https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Post Bariatric Hypoglycemia Market is set for steady growth, with a robust CAGR anticipated by 2034, estimates DelveInsight here
News-ID: 3851449 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Hypoglycemia
Hypoglycemia Market to Reach USD 2.5 Billion by 2034
Hypoglycemia, commonly defined as abnormally low blood glucose levels, is a serious condition that often affects individuals with diabetes receiving insulin or other glucose-lowering therapies. Symptoms range from dizziness, sweating, and confusion to seizures and coma in severe cases. Beyond diabetes, hypoglycemia can also result from metabolic disorders, hormone deficiencies, excessive alcohol intake, or post-surgical complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72031
With diabetes incidence rising globally and…
Severe Hypoglycemia Market to Reach USD 3.2 Billion by 2034
Severe hypoglycemia is a critical, potentially life-threatening condition marked by dangerously low blood glucose levels, most often occurring in patients with diabetes mellitus treated with insulin or insulin secretagogues. It can lead to seizures, unconsciousness, and, in extreme cases, death. Beyond the immediate medical risks, recurrent severe hypoglycemia significantly affects quality of life and increases the burden on healthcare systems.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72047
As the…
Postbariatric Hypoglycemia Market Growth, Applications, Innovations and Business …
Introduction
Postbariatric hypoglycemia (PBH) is an increasingly recognized complication of bariatric surgery, especially gastric bypass procedures. Characterized by low blood sugar after eating, PBH is often caused by rapid glucose absorption and exaggerated insulin release. Symptoms range from dizziness, fatigue, and palpitations to severe neuroglycopenic events like confusion, seizures, and unconsciousness.
With the global obesity epidemic driving higher rates of bariatric surgery, PBH cases are becoming more common. Growing awareness among physicians…
Hypoglycemia Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Upda …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoglycemia pipeline constitutes 10+ key companies continuously working towards developing 12+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Post-Bariatric Hypoglycemia Market Expected to rise, 2034 | Vogenx, Eiger BioPha …
The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric Hypoglycemia, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Post-Bariatric Hypoglycemia market report [https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Post-Bariatric Hypoglycemia market size, share, Post-Bariatric Hypoglycemia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and…
Postbariatric Hypoglycemia Treatment Market Size, Drugs, Emerging Therapies and …
Postbariatric Hypoglycemia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Postbariatric Hypoglycemia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Postbariatric Hypoglycemia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Postbariatric Hypoglycemia, historical and…
